The Effects of Melatonin Supplementation on Parameters of Mental Health, Glycemic Control, Markers of Cardiometabolic Risk, and Oxidative Stress in Diabetic Hemodialysis Patients: A Randomized, Double-Blind, Placebo-Controlled Trial by Ostadmohammadi, V. et al.
ORIGINAL RESEARCHThe Effects of Melatonin Supplementation
on Parameters of Mental Health, Glycemic
Control, Markers of Cardiometabolic Risk,
and Oxidative Stress in Diabetic
Hemodialysis Patients: A Randomized,
Double-Blind, Placebo-Controlled Trial
Vahidreza Ostadmohammadi, MD,* Alireza Soleimani, MD,† Fereshteh Bahmani, PhD,*
Esmat Aghadavod, PhD,* Reza Ramezani, MSc,* Russel J. Reiter, MD,‡
Mohammad Ali Mansournia, MD,§ Zarrin Banikazemi, MSc,* Maryam Soleimani, MD,*
Marsa Zaroudi, PhD,{ and Zatollah Asemi, PhD*
Objective: This study evaluated the effects of melatonin supplementation on parameters of mental health, glycemic control, markers
of cardiometabolic risk, and oxidative stress in diabetic hemodialysis (HD) patients.
Design: A randomized, double-blind, placebo-controlled clinical trial was conducted in 60 diabetic HD patients, 18-80 years of age.
Participants were randomly divided into 2 groups to take either melatonin (2 x 5mg/day) (n 5 30) or placebo (n 5 30) 1 hour before
bedtime for 12 weeks. The effects of melatonin on mental health, metabolic status, and gene expression related to metabolic status
were assessed using multiple linear regression adjusting for age and BMI.
Results: Melatonin supplementation significantly decreased Pittsburgh Sleep Quality Index (P 5 .007), Beck Depression Inventory
index (P 5 .001), and Beck Anxiety Inventory index (P 5 .01) compared with the placebo. Additionally, melatonin administration signif-
icantly reduced fasting plasma glucose (b5221.77 mg/dL, 95% CI233.22 to210.33, P, .001), serum insulin levels (b521.89 mIU/
mL, 95% CI 23.34 to 20.45, P 5 .01), and homeostasis model of assessment-insulin resistance (b 5 21.45, 95% CI 22.10 to 20.80,
P, .001), and significantly increased the quantitative insulin sensitivity check index (b5 0.01, 95% CI 0.007-0.02, P, .001) compared
with placebo treated subjects. In addition, melatonin administration resulted in a significant reduction in serum high sensitivity C-reactive
protein (b521.92 mg/L, 95% CI23.02 to20.83, P5 .001) and plasma malondialdehyde (b520.21 mmol/L, 95% CI20.36 to20.06,
P 5 .005); also, significant rises in plasma total antioxidant capacity (b 5 253.87 mmol/L, 95% CI 189.18-318.56, P , .001) and nitric
oxide levels (b 5 2.99 mmol/L, 95% CI 0.71-5.28, P 5 .01) were observed compared with the placebo.
Conclusion: Overall, melatonin supplementation for 12 weeks to diabetic HD patients had beneficial effects on mental health, glyce-
mic control, inflammatory markers, and oxidative stress.
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DIABETES MELLITUS IS a major risk factor forchronic kidney diseases and many affected people
develop diabetic nephropathy, the leading cause of
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ESRD receive hemodialysis (HD).1 Cardiovascular disease
(CVD) remains the most common cause of death in these
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OSTADMOHAMMADI ET AL2prevalent consequences in HD patients.3 Prior studies have
documented that both malnutrition and inflammation are
correlated with atherosclerosis progression and with an
increased risk of all-cause morbidity and mortality in HD
patients.4 Moreover, metabolic disorders including insulin
resistance, hyperinsulinemia, dyslipidemia, and increased
oxidative stress are prevalent in HD patients.5,6
Melatonin is an endogenous indoleamine that is synthe-
sized and secreted by the pineal gland.7 Both animal and
human studies suggest that melatonin administration may
improve components of metabolic syndrome, such as
elevated glucose and insulin resistance, hypertension, dysli-
pidemia, and obesity.8,9 In addition, epidemiologic studies
have reported an inverse relationship between melatonin
secretion and insulin resistance.10,11 Some studies have
also demonstrated the anti-inflammatory and antioxidant
effects of melatonin.12,13 In a study conducted by Quiroz
et al.,14 melatonin intake reduced oxidative stress, inflam-
mation, proteinuria, and the progression of renal damage
in rats with renal mass reduction. Oxidative stress and its
constant companion, inflammation, play key roles in the
pathogenesis of the progression of kidney injury.15 Mela-
tonin directly scavenge free radicals and stimulates the ac-
tivity and expression of antioxidant enzymes.16 It also
decreases gene expression related to inflammatory
markers.17 On the other side, circadian rhythms have
been demonstrated to be considerably disrupted in HD
subjects.18 Interestingly, melatonin production declines as
renal function decreases19 and in the majority of HD peo-
ple, the nighttime surge of serum melatonin is even
absent.20
Given the antioxidant and anti-inflammatory effects of
melatonin, we hypothesized that melatonin might be bene-
ficial in diabetic HD patients. The present study was, there-
fore, performed to evaluate the effects of melatonin
administration on parameters of mental health, metabolic
status, and gene expression related to metabolic status in
these patients.Methods
Trial Design and Participants
The current study is a randomized, double-blind, pla-
cebo-controlled clinical trial which was conducted with
the aid of 60 diabetic HD patients, 18-80 years between
February 2018 and June 2018. This intervention was
done in accordance with the Declaration of Helsinki and
informed consent was taken from all participants. Patients
with infectious, inflammatory, and malignant diseases,
those taking melatonin supplements, antioxidant, and/or
anti-inflammatory supplements within 3 months prior to
enrollment in the study, the night shift workers, and sub-
jects taking immunosuppressive and antibiotic medications
were not included in the current study.Downloaded for Anonymous User (n/a) at Kashan University of Medical 
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At the onset of the study, after balanced blocked random-
ization, all participants were allocated into two groups to
take either melatonin or placebo. Patients were requested
to continue their routine physical activity, and not to take
any anti-inflammatory and antioxidant medications or sup-
plements that might influence their nutritional status dur-
ing the 12-week treatment. Consumption of melatonin
and placebos throughout the study was checked by asking
subjects to return the medication containers. In addition,
a short message was sent to the cell phones of all patients
every day to remind participants to use the desired supple-
ments. A 3-day food records and physical activity records
were completed by all participants at weeks 0, 4, 7, and
12 of the intervention. To obtain macro- and micro-
nutrient intakes of participants based on these 3-day food
diaries, Nutritionist IV software (First Databank, San
Bruno, CA) was used.
Intervention
Patients were allocated into 2 groups to take either mela-
tonin capsule (23 5 mg/day) (n5 30) or placebo (n5 30)
1 hour before bedtime for 12 weeks. Melatonin and its pla-
cebowere produced in the same shape and package by Zah-
ravi Pharmaceutical Company (Tabriz, Iran).
Assessment of Anthropometric Measures
Body weight and height were quantified in an overnight
fasting status using a digital scale (Seca, Hamburg, Ger-
many) at baseline and after the 12-week intervention.
BMI was calculated by weight and height measurements
[weight (kg)/height (m2)].
Clinical Measures
Quality of sleep was determined using Pittsburgh Sleep
Quality Index (PSQI).21 Beck Depression Inventory
(BDI) was assessed using a self-compiled questionnaire of
21 items in multiple choice format.22 Anxiety was
measured using the Beck Anxiety Inventory (BAI)-21
questionnaire developed by Beck et al.23 to determine the
frequency of anxiety symptoms in adults.
Assessment of Outcomes
Insulin levels, the homeostasis model of assessment-
insulin resistance (HOMA-IR), and the quantitative insulin
sensitivity check index (QUICKI) were considered as pri-
mary outcomes and parameters of mental health, lipid pro-
files, and biomarkers of inflammation and oxidative stress
were considered secondary outcomes. Before the onset
and after the end of the intervention, 15 mL blood samples
before dialysis session after weekend were obtained from
each patient in an early morning after an overnight fast.
Fasting plasma glucose (FPG), hemoglobin A1c (HbA1c),
and lipid profiles were quantified on the day of blood
collection. Then, the samples were stored at280C before
analysis. Serum insulin and high sensitivity C-reactiveSciences from ClinicalKey.com by Elsevier on December 29, 2019.
 Copyright ©2019. Elsevier Inc. All rights reserved.
MELATONIN SUPPLEMENTATION AND DIABETIC HEMODIALYSIS 3protein (hs-CRP) levels were quantified by the use of an
enzyme-linked immunosorbent assay kit (DiaMetra, Mi-
lano, Italy; LDN, Nordhorn, Germany) with inter- and
intra-assay coefficient variances (CVs) of lower than 7%.
HOMA-IR and QUICKI were determined according to
the standard formula.24 HOMA-IR was calculated using
the following formula24: [FPG (mg/dL) 3 fasting serum
insulin (mU/mL)/405]. QUICKI was calculated using
the following formula24: [1/log fasting serum insulin
(mU/mL) 1 log FPG (mg/dL)]. HbA1c values in whole
blood were quantified by Glycomat kit (BiocodeHycel,
Massy, France) using the method of exchange chromatog-
raphy. Enzymatic kits (Pars Azmun, Tehran, Iran) were used
to quantify FPG, lipid profiles with inter- and intra-assay
CVs less than 5%. The plasma total nitrite was estimated us-
ing the Griess method, total antioxidant capacity (TAC) by
themethod of ferric reducing antioxidant power developed
by Benzie and Strain, total glutathione (GSH) using the
method of Beutler et al.,25 and malondialdehyde (MDA)
concentrations were determined by the thiobarbituric
acid reactive substances spectrophotometric test with inter-
and intra-assay CVs of lower than 5%. Systolic and diastolic
blood pressure was determined via a sphygmomanometer
(ALPK2, Zhejiang, China). Blood pressures were quanti-
fied between 08:00 and 09:00 AM by the same investigator
each time. Dialysis Kt/V was calculated using the 1993
Daugirdas equation.26
The questions of subjective global assessment question-
naire were also asked by the same person after 12 weeks
of the intervention. Then, the subjective global assessment
classifications were converted to numerical equivalents: a
score of ,10 points was regarded as well nourished;
10-17 points, at risk for malnutrition or mildly to moder-
ately malnourished; and more than 17 points, severely
malnourished.27
Isolation of Lymphocytes
Lymphocytes were extracted from participants’ blood
samples using 50% percoll (Sigma-Aldrich, Dorset, UK).
Cell count and viability test were conducted using trypan
blue, RNA, and DNA extraction.
RNA Extraction and Real-Time Polymerase
Chain Reaction
RNX-plus kit (Cinnacolon, Tehran, Iran) was used to
extract RNA from blood samples. RNA suspension was
frozen at 220C until complementary DNA was derived.
Following the extraction of total RNAs from each sample,
RNA quantification was performed using an ultra violet
spectrophotometer. Each sample optical density 260/280
ratio was considered to be between 1.7 and 2.1, demon-
strating no contamination with either protein or DNA.
The isolated RNAwas reverse transcribed to complemen-
tary DNA library, using moloney murine leukemia
virus reverse transcriptase. Gene expressions of peroxisome
proliferator-activated receptor gamma (PPAR-g),Downloaded for Anonymous User (n/a) at Kashan University of Medical S
For personal use only. No other uses without permission. Clow-density lipoprotein receptor (LDLR), interleukin-8
(IL-8), tumor necrosis factor alpha (TNF-a), and trans-
forming growth factor beta (TGF-b) were assessed by
quantitative real-time polymerase chain reaction in periph-
eral blood mononuclear cells (PBMCs), using the Light
Cycler technology (Roche Diagnostics, Rotkreuz,
Switzerland) with SYBR green detection and Amplicon
Kit (Table 1). Glyceraldehyde-3-phosphate dehydrogenase
primers were used as a housekeeping gene. Primer Express
Software (Applied Biosystems, Foster City, CA) and Bea-
con designer software (Takaposizt, Tehran, Iran) were
used to design primers. Relative transcription levels were
calculated using the method of Pffafi.
Sample Size
In this investigation, we used a randomized clinical trial
sample size calculation formula where type 1 (a) and type 2
errors (b) were 0.05 and 0.20 (power5 80%), respectively.
According to the previous trial,9 we used 2.20 as the stan-
dard deviation and 1.75 as the change in mean (d) of
HOMA-IR as a primary outcome. Based on the formula,
we needed 25 participants in each group; after allowing
for 5 dropouts in each group, the final sample size was 30
persons in each group.
Randomization
Randomization assignment was conducted using
computer-generated random numbers. Randomization
and allocation were hidden from the researchers and pa-
tients until the final analyses were completed. The random-
ized allocation sequence, enrolling participants, and
allocating them to interventions were conducted by a
trained nutritionist at the dialysis clinic.
Statistical Methods
The Kolmogorov-Smirnov test was done to determine
the normality of data. To detect the differences in anthro-
pometric measures, dietary intakes, and gene expression
between 2 groups, we used the independent-samples
t-test. Multiple linear regression model was used to assess
treatment effects on study outcomes after adjusting for con-
founding parameters including age and BMI. The effect
sizes were presented as the mean differences with 95% con-
fidence intervals. P-values ,.05 were considered statisti-
cally significant. All statistical analyses were done using
the Statistical Package for Social Science version 18 (SPSS
Inc., Chicago, IL).
Results
In the melatonin group, a total of 4 participants were
excluded from the study: 2 patients were excluded because
of changes in treatment protocol and 2 patients were un-
willing to continue for personal reasons. In the placebo
group, 3 patients were excluded: 1 patient was excluded
because of changes in treatment protocol and 2 patients
were unwilling to continue for personal reasons. Finally,ciences from ClinicalKey.com by Elsevier on December 29, 2019.
opyright ©2019. Elsevier Inc. All rights reserved.
Table 1. Specific Primers Used for Real-Time Quantitative PCR
Gene Primer Product Size (bp) Annealing Temperature (C)
GAPDH F: AAGCTCATTTCCTGGTATGACAACG 126 61.3
R: TCTTCCTCTTGTGCTCTTGCTGG
TNF-a F: GTCAACCTCCTCTCTGCCAT 188 52
R: CCAAAGTAGACCTGCCCAGA
IL-8 F: GCAGAGGGTTGTGGAGAAGT 150 56
R: ACCCTACAACAGACCCACAC
TGF-b F: TTGAGACTTTTCCGTTGCCG 227 56
R: CGAGGTCTGGGGAAAAGTCT
PPAR-g F: ATGACAGACCTCAGACAGATTG 210 54
R: AATGTTGGCAGTGGCTCAG
LDLR F: ACTTACGGACAGACAGACAG 223 57
R: GGCCACACATCCCATGATTC
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; IL-8, interleukin-8; LDLR, low-density lipoprotein receptor; PCR, polymerase chain re-
action; PPAR-g, peroxisome proliferator-activated receptor gamma; TNF-a, tumor necrosis factor alpha; TGF-b, transforming growth factor
beta.
OSTADMOHAMMADI ET AL453 patients [melatonin (n 5 26) and placebo (n 5 27)]
completed the study (Fig. 1). The compliance rate was
high; more than 90% of capsules were taken during the
course of the trial in both groups. No side effects were re-
ported following the consumption of melatonin supple-
ments in diabetic HD patients throughout the study.
During the 12-week intervention period, no adverse event
such as hypotension, CVD, and hyperglycemia has been
reported.
Distribution of gender, mean age, height, baseline
weight, and BMI as well as their means after intervention,
and years of dialysis of study participants were not statisti-
cally different between the 2 groups (Table 2).
Based on the 3-day dietary records obtained throughout
the treatment period, we found no significant change in di-
etary macro- and micro-nutrient intakes (data not shown).
After the 12-week intervention, melatonin supplementa-
tion significantly decreased PSQI (b 5 22.41, 95% confi-
dence interval [CI] 24.13 to 20.69, P 5 .007), BDI
(b 5 23.52, 95% CI 25.50 to21.55, P 5 .001), and BAI
(b 5 21.92, 95% CI 23.51 to 20.33, P 5 .01) compared
with the placebo (Table 3). Additionally, melatonin supple-
mentation significantly reduced FPG (b 5 221.77 mg/
dL, 95% CI 233.22 to 210.33, P , .001), serum insulin
levels (b 5 21.89 mIU/mL, 95% CI 23.34 to 20.45,
P 5 .01), HOMA-IR (b 5 21.45, 95% CI 22.10 to
20.80, P , .001), and HbA1c (b 5 20.58%, 95% CI
21.16 to 20.002, P 5 .04), and significantly increased
QUICKI (b 5 0.01, 95% CI 0.007-0.02, P , .001)
comparedwith the placebo. In addition, melatonin adminis-
tration resulted in a significant reduction in serum hs-CRP
(b 5 21.92 mg/L, 95% CI 23.02 to 20.83, P 5 .001)
and plasma MDA (b 5 20.21 mmol/L, 95% CI 20.36 to
20.06, P 5 .005); also, significant rises in plasma TAC (b
5 253.87 mmol/L, 95% CI 189.18-318.56, P , .001) and
NO levels (b 5 2.99 mmol/L, 95% CI 0.71-5.28, P 5 .01)
were observed compared with the placebo. Melatonin sup-
plementation did not change other metabolic parameters.Downloaded for Anonymous User (n/a) at Kashan University of Medical 
For personal use only. No other uses without permission.Melatonin supplementation upregulated gene expres-
sion of PPAR-g (P5.03), and downregulated gene expres-
sion of IL-8 (P5.03) and TNF-a (P5.008) in PBMCs of
subjects with diabetic HD, compared with the placebo;
melatonin did not affect gene expression of LDLR and
TGF-b (Fig. 2).
Discussion
In the current study, we investigated the effects of mela-
tonin supplementation on metabolic profiles among dia-
betic HD subjects. We found that melatonin
supplementation for 12 weeks to diabetic HD patients
had favorable effects on BDI, BAI, PSQI index, FPG, insu-
lin levels, HOMA-IR, HbA1c, QUICKI, hs-CRP, total
nitrite, TAC and MDA, and gene expression of IL-8,
TNF-a, and PPAR-g, but did not affect other metabolic
profiles and gene expression of LDLR and TGF-b. Several
studies evaluated the effects of melatonin supplementation
on metabolic profiles in patients with metabolic disorders.
Although the efficacy of melatonin has been examined in
diabetic patients with CHD,9 we are aware of no study
examining the effects of melatonin supplementation on
metabolic profiles in diabetic HD subjects. However, we
have previously shown that melatonin intake at a dosage
of 10 mg/day for 12 weeks in diabetic patients with
CHD had beneficial effects on plasma GSH, total nitrite,
MDA, serum hs-CRP levels, glycemic control, HDL-
cholesterol, total-/HDL-cholesterol ratio, blood pressures,
and parameters of mental health,9 in the current study, we
demonstrated that melatonin supplementation for 12weeks
to diabetic HD subjects had favorable effects on BDI, BAI,
PSQI index, FPG, insulin levels, HOMA-IR, HbA1c,
QUICKI, hs-CRP, total nitrite, TAC, and MDA levels.
In the present study, we did not observe any significant ef-
fect of melatonin intake on lipid profiles and blood pres-
sures. Raygan et al.9 did not examine the effect of
melatonin supplementation on gene expression related to
insulin, lipid, and inflammatory cytokines, while weSciences from ClinicalKey.com by Elsevier on December 29, 2019.
 Copyright ©2019. Elsevier Inc. All rights reserved.
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Figure 1. Summary of patient flow diagram.
MELATONIN SUPPLEMENTATION AND DIABETIC HEMODIALYSIS 5assessed the effect of melatonin supplementation on these
biomarkers as well.
Effects on Glycemic Control and Lipid Profiles
This study documented that melatonin administration for
12 weeks to diabetic HD patients significantly decreased
FPG, insulin concentrations, HOMA-IR, and HbA1c, and
significantly increased QUICKI while it did not affect lipidTable 2. General Characteristics of Study Participants
Placebo Gr
Gender (%)
Male 20 (
Female 7 (2
Age (y) 64.1
Height (cm) 168.9
Weight at study baseline (kg) 75.0
Weight at end-of-trial (kg) 74.9
Weight change (kg) 20.1
BMI at study baseline (kg/m2) 26.4
BMI at end-of-trial (kg/m2) 26.4
BMI change (kg/m2) 20.04
Dialysis Kt/V urea 1.9
Residual renal function at study baseline (mL/min) 3.0
Dialysis duration per week (h) 10.3
Years on dialysis 3.7
BMI, body mass index; SD, standard deviation.
Data are represented as mean 6 SD.
*Obtained from independent t-test.
†Obtained from Pearson chi-squared test.
Downloaded for Anonymous User (n/a) at Kashan University of Medical S
For personal use only. No other uses without permission. Cprofiles. In addition, melatonin supplementation upregulated
gene expression of PPAR-g in PBMCs of patients with HD,
but did not influence gene expression of LDLR.Both animal
and human studies have previously investigated the effects of
melatonin supplementation on glucose metabolism and lipid
profiles. In a rat model of DM, melatonin administration for
30 weeks attenuated the development of hyperinsulinemia,
hypertriglyceridemia, and hyperleptinaemia.28 In addition,oup (n 5 27) Melatonin Group (n 5 26) P Value*
74.1) 18 (69.2) .69†
5.9) 8 (30.8)
6 8.2 65.6 6 13.1 .60
6 7.1 169.9 6 8.5 .64
6 13.3 75.5 6 14.8 .89
6 13.0 75.4 6 14.7 .88
6 1.1 20.05 6 1.3 .89
6 5.9 26.4 6 4.7 .84
6 5.4 26.1 6 4.6 .85
6 0.4 20.02 6 0.4 .80
6 0.6 2.1 6 0.7 .45
6 0.6 3.2 6 0.8 .41
6 2.4 10.6 6 2.5 .68
6 1.3 3.6 6 1.2 .71
ciences from ClinicalKey.com by Elsevier on December 29, 2019.
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Table 3.Metabolic Profiles, Biomarkers of Inflammation, andOxidative Stress at Study Baseline After the 12-Week Intervention
in Patients With Diabetic Hemodialysis That Received Either Melatonin Supplements or Placebo
Variables
Placebo Group (n 5 27) Melatonin Group (n 5 26)
Difference in Outcome Measures
Between Melatonin and
Placebo Treatment Groups*
Baseline Wk 12 Baseline Wk 12 b (95% CI) P Value†
PSQI 10.7 6 3.2 9.9 6 3.4 11.1 6 3.2 7.4 6 2.8 22.41 (24.13 to 20.69) .007
BDI score 26.2 6 4.9 24.8 6 5.0 27.3 6 5.1 21.9 6 3.9 23.52 (25.50 to 21.55) .001
BAI score 18.6 6 3.9 18.1 6 4.5 20.8 6 4.7 17.9 6 4.3 21.92 (23.51 to 20.33) .01
FPG (mg/dL) 125.3 6 63.8 131.4 6 62.5 127.1 6 40.5 112.1 6 36.7 221.77 (233.22 to 210.23) ,.001
Insulin (mIU/mL) 14.0 6 5.0 14.7 6 5.1 13.9 6 4.2 12.6 6 4.1 21.89 (23.34 to 0.45) .01
HOMA-IR 4.0 6 1.5 4.6 6 2.2 4.4 6 2.0 3.5 6 1.7 21.45 (22.10 to 20.80) ,.001
QUICKI 0.31 6 0.01 0.31 6 0.01 0.31 6 0.02 0.32 6 0.02 0.01 (0.007-0.02) ,.001
HbA1c (%) 6.9 6 1.6 7.0 6 1.8 7.2 6 0.9 6.7 6 1.0 20.58 (21.16 to 20.002) .04
Triglycerides (mg/dL) 132.2 6 59.7 125.7 6 60.1 133.5 6 69.6 115.4 6 73.8 211.50 (228.16 to 5.15) .17
VLDL-cholesterol (mg/dL) 26.4 6 11.9 25.1 6 12.0 26.7 6 13.9 23.1 6 14.8 22.30 (25.63 to 1.03) .17
Total cholesterol (mg/dL) 124.6 6 20.4 122.3 6 24.7 128.7 6 39.3 114.7 6 39.7 29.45 (224.86 to 5.96) .22
LDL-cholesterol (mg/dL) 67.0 6 18.4 65.8 6 23.6 71.2 6 28.5 60.0 6 32.3 27.78 (221.96 to 6.39) .27
HDL-cholesterol (mg/dL) 31.2 6 4.9 31.4 6 5.3 30.8 6 6.0 31.6 6 6.1 0.64 (21.29 to 2.58) .50
hs-CRP (mg/L) 5.7 6 3.2 5.8 6 3.6 5.4 6 2.8 3.7 6 2.5 21.92 (23.02 to 20.83) .001
Total nitrite (mmol/L) 33.1 6 4.8 32.8 6 6.1 36.9 6 3.9 38.9 6 4.0 2.99 (0.71-5.28) .01
TAC (mmol/L) 786.5 6 68.5 760.5 6 73.9 889.92 6 103.2 1064.5 6 131.6 253.87 (189.18-318.56) ,.001
GSH (mmol/L) 498.0 6 82.7 497.8 6 86.7 479.7 6 62.5 497.6 6 62.8 9.81 (222.81 to 42.44) .54
MDA (mmol/L) 2.9 6 0.6 3.0 6 0.7 2.7 6 0.2 2.6 6 0.3 20.21 (20.36 to 20.06) .005
SGA score 10.9 6 2.0 11.3 6 2.1 10.7 6 2.4 10.5 6 2.7 20.59 (21.38 to 0.20) .20
Creatinine (mg/dL) 8.2 6 3.0 8.1 6 2.8 7.5 6 3.0 7.4 6 2.5 20.12 (20.61 to 0.36) .61
BUN (mg/dL) 56.9 6 18.4 56.2 6 12.6 60.1 6 27.9 59.4 6 27.1 2.15 (28.75 to 13.05) .69
SBP (mm Hg) 124.8 6 11.6 122.0 6 8.6 123.3 6 10.9 120.4 6 9.9 20.65 (24.43 to 3.12) .72
DBP (mm Hg) 74.6 6 7.5 75.5 6 7.2 77.5 6 6.2 76.9 6 7.2 0.60 (23.33 to 4.50) .75
BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory; BMI, body mass index; BUN, blood urea nitrogen; CI, confidence interval; DBP,
diastolic blood pressure; FPG, fasting plasma glucose; GSH, total glutathione; HDL-cholesterol, high density lipoprotein-cholesterol; HOMA-IR,
homeostasis model of assessment-insulin resistance; hs-CRP, high sensitivity C-reactive protein; LDL-cholesterol, low density lipoprotein-
cholesterol; MDA, malondialdehyde; PSQI, Pittsburgh Sleep Quality Index; QUICKI, quantitative insulin sensitivity check index; SBP, systolic
blood pressure; SD, standard deviation; SGA, subjective global assessment; TAC, total antioxidant capacity; VLDL-cholesterol, very low density
lipoprotein-cholesterol.
Data are represented as mean 6 SD.
*‘‘Outcomemeasures’’ refer to the change in values of measures of interest between baseline and week 12. b [difference in the mean outcome
measures between treatment groups (melatonin group 5 1 and placebo group 5 0)].
†Obtained from multiple regression model (adjusted for baseline values of each biochemical variables, age, and baseline BMI).
OSTADMOHAMMADI ET AL6melatonin supplementation in combination with exercise
significantly improved insulin resistance and hypertension
via upregulation of GLUT-4, PPAR-g coactivator 1a, and
mitochondrial biogenesis in type 2 diabetes mellitus rats.29
Sun et al.30 also demonstrated that taking melatonin at a
dosage of 3mg/day for 12weeks byobese people significantly
decreased insulin levels and HOMA-IR score. Recently, we
documented that consuming melatonin for 12 weeks by dia-
betic patients with CHD had beneficial effects on glycemic
control, HDL-cholesterol, and total-/HDL-cholesterol ra-
tio.9 In a meta-analysis, melatonin intake had significant ef-
fects on triglycerides and total cholesterol concentrations,
but did not influence other lipid profiles.31 However, supple-
mentation with 6 mg/day of melatonin for 2 weeks increased
VLDL-cholesterol, but did not change HDL- and LDL-
cholesterol levels in postmenopausal women.32 This differ-
ence in the results of various studies could be correlated
with the differences in the type of studied diseases, dosage
of melatonin used, and duration of the intervention. BasedDownloaded for Anonymous User (n/a) at Kashan University of Medical 
For personal use only. No other uses without permission.on previous clinical trials and meta-analyses, high dose
($8 mg) and/or long period (.8 weeks) melatonin supple-
mentation might showmore benefits in improving glycemic
indicators, serum lipids, inflammatorymarkers, and oxidative
stress parameters,33,34 while low dose and/or short period
administration of melatonin did not affect metabolic
profiles.35-37 Due to lack of evidence about the appropriate
dosage of melatonin for diabetic HD patients, we used
dosage and duration of melatonin based on a previous study
in diabetic patients with CHD.9 Therefore, higher dose of
melatonin supplementation or a longer intervention period
in diabetic HD patients might ameliorate lipid profiles and
other metabolic outcomes. Melatonin receptors (MT1 and
MT2) have been documented to be present on the adipocytes
and the beta cells of the human pancreatic islets. The effects of
melatonin on insulin secretion may be mediated through
these receptors.38 Melatonin can decrease insulin secretion
by inhibiting cyclic adenosine monophosphate and cyclic
guanosine monophosphate pathways.39Sciences from ClinicalKey.com by Elsevier on December 29, 2019.
 Copyright ©2019. Elsevier Inc. All rights reserved.
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Figure 2. Effect of the 12-week supplementation with melatonin or placebo on expression ratio of PPAR-g, LDLR, TNF-a, IL-8,
and TGF-b gene in PBMCs of diabetic HD patients. HD, hemodialysis; IL-8, interleukin-8; LDLR, low-density lipoprotein receptor;
PBMCs, peripheral blood mononuclear cells; PPAR-g, peroxisome proliferator-activated receptor gamma; TNF-a, tumor necro-
sis factor alpha; TGF-b, transforming growth factor beta.
MELATONIN SUPPLEMENTATION AND DIABETIC HEMODIALYSIS 7Effects on Parameters of Mental Health,
Biomarkers of Inflammation, and Oxidative
Stress
We found that taking melatonin by diabetic HD patients
for 12 weeks resulted in a significant reduction in BDI,
BAI, PSQI, hs-CRP, and MDA, and a significant elevation
in TAC and total nitrite levels, but melatonin did not affect
GSH levels. Moreover, melatonin administration downre-
gulated IL-8 and TNF-a gene expression in PBMCs of HD
patients, but did not influence gene expression of TGF-b.
Interventional studies have demonstrated that melatonin
has antioxidant and anti-inflammatory functions,40 but
the results have not always been consistent. In a study
conducted by Hussein et al.,41 melatonin administration
(1 mg/kg/day) to obese rabbits for 4 weeks significantly
increased TAC levels. Melatonin consumption at a dosage
of 5 mg/day among subjects with metabolic syndrome after
8 weeks reduced MDA and increased catalase activity.13
Recently, we reported that consuming melatonin for
12 weeks by diabetic patients with CHD had beneficial ef-
fects on some inflammatory factors, oxidative stress, and pa-
rameters of mental health.9 Leppamaki et al.42 found that
melatonin administration at a dosage of 20 mg/day for
3 weeks significantly improved the quality of sleep, vitality,
and quality of life in subjects with weather-associated syn-
drome. However, melatonin consumption (6 mg/day for
40 days) in obese women did not affect TAC and MDADownloaded for Anonymous User (n/a) at Kashan University of Medical S
For personal use only. No other uses without permission. Clevels.12 In addition, melatonin intake did not affect cogni-
tion, well-being, or psychosocial functioning in people
with severe mental illness.43 Increased oxidative stress and
inflammationwhich presented in ESRDpatients can inten-
sify each other and are associated with a large number of
ESRD complications including protein energy wasting,
atherosclerosis, and all-cause and CVD mortality.44 There-
fore, the finding of a beneficial impact of melatonin admin-
istration on inflammatory status and oxidative damage has
great implications in the context of ESRD and there may
be important advantages for HD people including prevent-
ing cardiovascular events, reducing protein energy wasting,
and even mortality rate.45-47 Melatonin may improve
parameters of mental health, inflammatory markers, and
oxidative damage through regulating the activities of
antioxidative enzymes,48 stimulating glutathione synthe-
sis49 and suppressing nuclear factor-kappaB activation.50,51
Prior human and animal studies documented that mela-
tonin has a safety profilewithout any serious adverse effects,
even in high doses. Only minimal side effects such as sleep-
iness, dizziness, nausea, and headache have been reported.52
It must be kept in mind that the time of melatonin con-
sumption is very important. Administration of melatonin
in the morning and evening increases insulin-resistant and
impairs glucose tolerance,53 whereas nighttime melatonin
intake can decrease the release of insulin in response to a
rise in circulating glucose levels.9 Furthermore, melatoninciences from ClinicalKey.com by Elsevier on December 29, 2019.
opyright ©2019. Elsevier Inc. All rights reserved.
OSTADMOHAMMADI ET AL8has sedative effects and bed-time melatonin consumption
could enhance the quality of sleep.54 Melatonin has been
identified in some kinds of foods. In animal foods, fish
and eggs are rich sources of dietary melatonin, whereas in
plant foods, cereals, germinated legumes, nuts, and mush-
rooms are also the highest melatonin-containing foods.55
In our trial, based on 3-day food records, both groups are
similar in terms of dietary intakes and various dietary pat-
terns among participants cannot confound the results.
There are a few limitations in the current investigation.
Due to budget limitations, we did not assess plasma or sali-
vary melatonin levels and urinary 6-sulfatoxymelatonin.
Also, wewere unable to determine the impact of melatonin
administration on other biomarkers of oxidative stress and
inflammatory factors such as IL-6 and IL-1. During the
baseline interview, PSQI questionnaire was completed for
our subjects, though we did not analyze sleep behaviors
of study participants according to PSQI criteria at baseline.
At final data analysis, we found out that few participants had
sleep problems. However, we also had asked the patients for
taking sleep medications. And, since none of them were
consuming sleep medications, we did not exclude anyone
from the study, although those with sleep problem had
been referred to specialist. This should be considered in
the interpretation of our findings.Conclusions
Overall, melatonin supplementation for 12weeks by dia-
betic HD patients had favorable effects on BDI, BAI, PSQI
index, FPG, insulin levels, HOMA-IR, HbA1c, QUICKI,
hs-CRP, total nitrite, TAC, andMDA, and gene expression
of IL-8, TNF-a, and PPAR-g, but did not affect other
metabolic profiles and gene expression of LDLR and
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